Skip to main content
TipRanks
Go Ultimate75% OFF

Kusurinomadoguchi, Inc. (5592) AI Stock Analysis

0 Followers
JP:5592

Kusurinomadoguchi, Inc.

(TSE/TYO:5592)

Select Model
Rating:83Outperform
Price Target:JPY 2,493.00â–²(16.50% Upside)
Action:reiterated
Date:08/17/26

Kusurinomadoguchi earns a strong overall score of 83, primarily driven by an attractive valuation and exceptional fundamental growth. The company boasts robust revenue and net income expansion, which is currently undervalued by the market as indicated by its low P/E ratio of 10.94. Additionally, technical indicators show strong positive momentum, with the stock trading firmly above all key moving averages.

Positive Factors
Revenue and profit growthThe sustained increase in revenue and net income indicates that the platform has expanded its commercial scale while improving profitability. This provides a stronger earnings base for the next several quarters and supports continued investment in the company’s healthcare-related digital services.
Negative Factors
Volatile leverage and assetsLarge changes in debt and total assets make the balance sheet less predictable and complicate assessment of the company’s steady-state financial position. Renewed borrowing after the 2025 low also means financial flexibility remains more variable than the stronger equity trend alone suggests.

Kusurinomadoguchi, Inc. (5592) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%JP:5592-19.57%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 24.37B
Dividend Yield
1.78%
Average Volume (3M)
54.82K
Price to Earnings (P/E)
7.6
Beta (1Y)
0.86
Revenue Growth
18.66%
EPS Growth
-10.20%
Country
Japan
Employees
491
Sector
General
Sector Strength
55
Industry
Medical - Healthcare Information Services

Kusurinomadoguchi, Inc. Business Overview & Revenue Model

Company Description

Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its compreh...

Kusurinomadoguchi, Inc. Financial Statement Overview

Summary

Kusurinomadoguchi exhibits a robust financial profile driven by exceptional revenue and net income growth, alongside a strong balance sheet with manageable debt. While cash flows showed historical volatility, the strong recovery in 2026 reinforces long-term financial stability.

Income Statement

88Very Positive

Balance Sheet

82Very Positive

Cash Flow

68Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue13.06B12.33B11.20B8.72B7.42B6.49B
Gross Profit7.38B6.97B6.48B4.93B4.07B3.37B
EBITDA4.38B4.19B2.97B2.35B1.68B1.51B
Net Income3.19B2.95B2.03B870.92M391.45M515.61M
Balance Sheet
Total Assets18.23B17.82B12.16B23.07B12.22B11.02B
Cash, Cash Equivalents and Short-Term Investments4.51B5.20B2.15B14.59B5.95B5.02B
Total Debt2.88B2.82B72.47M5.42B137.49M149.56M
Total Liabilities6.77B6.35B3.64B16.65B9.43B8.06B
Stockholders Equity11.35B11.35B8.45B6.37B2.70B2.45B
Cash Flow
Free Cash Flow02.93B-5.37B999.21M1.57B2.58B
Operating Cash Flow02.95B-5.33B2.63B3.10B3.66B
Investing Cash Flow0-2.30B-1.80B-1.79B-1.54B-541.10M
Financing Cash Flow02.22B-5.36B7.81B-635.39M-564.83M

Kusurinomadoguchi, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price2140.00

Price Trends

50DMA2472.08Negative
100DMA2469.92Negative
200DMA2561.63Negative

Market Momentum

MACD-113.17Positive
RSI36.10Neutral
STOCH34.74Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:5592, the sentiment is Negative. The current price of 2140.00 is below the 20-day moving average (MA) of 2248.95, below the 50-day MA of 2472.08, and below the 200-day MA of 2561.63, indicating a bearish trend. The MACD of -113.17 indicates Positive momentum. The RSI at 36.10 is Neutral, neither overbought nor oversold. The STOCH value of 34.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:5592.

Kusurinomadoguchi, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:5592 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:5592JP:559283OutperformJPY 23.59B7.56―1.78%18.66%-10.20%
JP:4483JP:448372OutperformJPY 251.97B33.34―0.48%20.50%19.27%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4438JP:443854NeutralJPY 2.30B-4.39――14.84%30.67%
JP:4480JP:448054NeutralJPY 82.95B38.4812.35%―21.01%10.15%
JP:4263JP:426340UnderperformJPY 4.17B-9.13――42.52%-81.61%

* General Sector Average

Performance Comparison

-50%-25%0%25%JP:5592JP:4480JP:4263JP:4438JP:4483Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:5592 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:5592Kusurinomadoguchi, Inc.2140.00-542.49-20.22%
JP:4480Medley, Inc.2108.00-447.00-17.50%
JP:4263SUSMED,Inc.252.00-658.00-72.31%
JP:4438Welby Inc.274.00-57.00-17.22%
JP:4483JMDC Inc.3740.00-514.30-12.09%

Kusurinomadoguchi, Inc. Corporate Events

Kusurinomadoguchi Maps Out Q1 Results and Multi‑Year Healthcare Tech Strategy

Aug 18, 2026

Kusurinomadoguchi, Inc. reported its financial results for the first quarter of the fiscal year ending March 2027, outlining performance across its main healthcare technology segments. The briefing indicates that management is using this reporting pe...

Kusurinomadoguchi Delivers Strong Q1 as New Acquisitions Lift Earnings

Aug 18, 2026

Kusurinomadoguchi reported robust Q1 FY2027 consolidated results, with revenue rising 25.0% year on year to ¥3,643 million and net income attributable to owners of the parent surging 61.0% to ¥623 million. Earnings per share climbed to ¥54.43, while...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026